Correlation Between Biomea Fusion and Akero Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Biomea Fusion and Akero Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Biomea Fusion and Akero Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Biomea Fusion and Akero Therapeutics, you can compare the effects of market volatilities on Biomea Fusion and Akero Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Biomea Fusion with a short position of Akero Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Biomea Fusion and Akero Therapeutics.

Diversification Opportunities for Biomea Fusion and Akero Therapeutics

-0.37
  Correlation Coefficient

Very good diversification

The 3 months correlation between Biomea and Akero is -0.37. Overlapping area represents the amount of risk that can be diversified away by holding Biomea Fusion and Akero Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Akero Therapeutics and Biomea Fusion is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Biomea Fusion are associated (or correlated) with Akero Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Akero Therapeutics has no effect on the direction of Biomea Fusion i.e., Biomea Fusion and Akero Therapeutics go up and down completely randomly.

Pair Corralation between Biomea Fusion and Akero Therapeutics

Given the investment horizon of 90 days Biomea Fusion is expected to under-perform the Akero Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Biomea Fusion is 2.48 times less risky than Akero Therapeutics. The stock trades about -0.26 of its potential returns per unit of risk. The Akero Therapeutics is currently generating about 0.09 of returns per unit of risk over similar time horizon. If you would invest  3,210  in Akero Therapeutics on November 29, 2024 and sell it today you would earn a total of  1,565  from holding Akero Therapeutics or generate 48.75% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Biomea Fusion  vs.  Akero Therapeutics

 Performance 
       Timeline  
Biomea Fusion 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Biomea Fusion has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's technical and fundamental indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Akero Therapeutics 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Akero Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Akero Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Biomea Fusion and Akero Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Biomea Fusion and Akero Therapeutics

The main advantage of trading using opposite Biomea Fusion and Akero Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Biomea Fusion position performs unexpectedly, Akero Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will offset losses from the drop in Akero Therapeutics' long position.
The idea behind Biomea Fusion and Akero Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Complementary Tools

Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Fundamental Analysis
View fundamental data based on most recent published financial statements
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like